$SYRE filed an 8-K with results (Item 2.02) at 4:02 PM ET on Tue, Nov 3.
Vote
SYRE
Spyre Therapeutics, Inc.$93.00CS band Mixed
+$3.76 (3.94%) At close $99.27 · Today
☾After Hours −$6.27 (6.32%) Nov 3, 7:59 PM ET
About SYRE
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Why it moved
Filed an 8-K today reporting results of operations · per SEC
Sources: SEC
From SEC filing · Not investment advice
Why it moved
Filed an 8-K today reporting results of operations · per SEC
From the company’s SEC filing: what was filed, no summary.
Sources: SEC
Written 5:01 PM ET · last check 7:30 PM ET
From SEC filing · Not investment adviceSign up free to see this.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Sentiment
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about SYRE?
Board · 0 threads
Open board ›Community opinions, not advice. Posts with a target get a receipt. How receipts work ›